Quarterly ResultJul 30, 2026, 06:56 AM
Regeneron Q2 Revenue +16.7% to $4.29B; EPS $12.23; EYLEA Patent Issues
AI Summary
Regeneron Pharmaceuticals reported a 16.7% increase in total revenue to $4,290.7 million for Q2 2026, primarily driven by a significant rise in collaboration revenue. However, diluted EPS decreased by 4.5% to $12.23. While U.S. EYLEA HD sales showed strong growth, U.S. EYLEA sales experienced a substantial decline. The company also faces ongoing legal challenges regarding its EYLEA patents, with some unfavorable outcomes in European patent proceedings.
Key Highlights
- Q2 2026 total revenue increased 16.7% to $4,290.7 million compared to Q2 2025.
- Q2 2026 diluted EPS decreased 4.5% to $12.23 from $12.81 in Q2 2025.
- Q2 2026 net product sales were $1,642.4 million, a slight increase of 0.7% YoY.
- Q2 2026 collaboration revenue surged 31.9% to $2,455.0 million.
- U.S. EYLEA HD sales grew 51.6% to $596.3 million in Q2 2026.
- U.S. EYLEA sales declined 45.4% to $412.2 million in Q2 2026.
- The company repurchased $1,967.7 million of common stock year-to-date 2026.
- EPO revoked two EYLEA patents ('306 and '049), and a German court suspended an injunction for the '691 patent.
Price Impact
More from REGN